Hua Zhou1, Yuexing Zhang, Anne W Hamburger. 1. Greenebaum Cancer Center, University of Maryland School of Medicine, 655 West Baltimore Street, BRB 9-029, Baltimore, MD 21201, U.S.A.
Abstract
BACKGROUND: Therapies that inhibit androgen receptor (AR) are needed for treatment of castration-resistant prostate cancer (CRPC). The ErbB3 binding protein 1 (EBP1) reduces protein expression of both AR and its target genes in CRPC. Although EBP1 regulates AR in hormone-sensitive prostate cancer cells, by both destabilizing AR mRNA and inhibiting protein translation, the mechanism of EBP1 down regulation of AR in CRPC is unknown. MATERIALS AND METHODS: Western blot and quantitative PCR analysis of cell lysates and polysomes were used to assess AR mRNA, protein expression and translation. RESULTS: In contrast to hormone- dependent cells, EBP1 did not change steady state levels of AR mRNA or AR mRNA stability in hormone refractory cells. EBP1 did slow protein translation of AR mRNA. The ErbB3/4 ligand heregulin further diminished AR translation in EBP1 -transfected cells, but not in control cells. CONCLUSION: These studies suggest that one pathway of EBP1 down-regulation of AR levels may be lost in CRPC.
BACKGROUND: Therapies that inhibit androgen receptor (AR) are needed for treatment of castration-resistant prostate cancer (CRPC). The ErbB3 binding protein 1 (EBP1) reduces protein expression of both AR and its target genes in CRPC. Although EBP1 regulates AR in hormone-sensitive prostate cancer cells, by both destabilizing AR mRNA and inhibiting protein translation, the mechanism of EBP1 down regulation of AR in CRPC is unknown. MATERIALS AND METHODS: Western blot and quantitative PCR analysis of cell lysates and polysomes were used to assess AR mRNA, protein expression and translation. RESULTS: In contrast to hormone- dependent cells, EBP1 did not change steady state levels of AR mRNA or AR mRNA stability in hormone refractory cells. EBP1 did slow protein translation of AR mRNA. The ErbB3/4 ligand heregulin further diminished AR translation in EBP1 -transfected cells, but not in control cells. CONCLUSION: These studies suggest that one pathway of EBP1 down-regulation of AR levels may be lost in CRPC.
Authors: E V Pilipenko; T V Pestova; V G Kolupaeva; E V Khitrina; A N Poperechnaya; V I Agol; C U Hellen Journal: Genes Dev Date: 2000-08-15 Impact factor: 11.361
Authors: Bu B Yeap; Dominic C Voon; Julian P Vivian; Ross K McCulloch; Andrew M Thomson; Keith M Giles; Maria F Czyzyk-Krzeska; Henry Furneaux; Matthew C J Wilce; Jackie A Wilce; Peter J Leedman Journal: J Biol Chem Date: 2002-05-13 Impact factor: 5.157
Authors: Yuexing Zhang; Joseph D Fondell; Qianben Wang; Xianmin Xia; Aiwu Cheng; Michael L Lu; Anne W Hamburger Journal: Oncogene Date: 2002-08-15 Impact factor: 9.867
Authors: Hua Zhou; Krystyna Mazan-Mamczarz; Jennifer L Martindale; Andrew Barker; Zhenqiu Liu; Myriam Gorospe; Peter J Leedman; Ronald B Gartenhaus; Anne W Hamburger; Yuexing Zhang Journal: Nucleic Acids Res Date: 2010-02-16 Impact factor: 16.971
Authors: Ingo K Mellinghoff; Igor Vivanco; Andrew Kwon; Chris Tran; John Wongvipat; Charles L Sawyers Journal: Cancer Cell Date: 2004-11 Impact factor: 31.743
Authors: Ansul Lokdarshi; Csaba Papdi; Aladár Pettkó-Szandtner; Stefan Dorokhov; Ben Scheres; Zoltán Magyar; Albrecht G von Arnim; László Bögre; Beatrix M Horváth Journal: Plant Physiol Date: 2019-12-09 Impact factor: 8.340
Authors: Sarah A Loddick; Sarah J Ross; Andrew G Thomason; David M Robinson; Graeme E Walker; Tom P J Dunkley; Sandra R Brave; Nicola Broadbent; Natalie C Stratton; Dawn Trueman; Elizabeth Mouchet; Fadhel S Shaheen; Vivien N Jacobs; Marie Cumberbatch; Joanne Wilson; Rhys D O Jones; Robert H Bradbury; Alfred Rabow; Luke Gaughan; Chris Womack; Simon T Barry; Craig N Robson; Susan E Critchlow; Stephen R Wedge; A Nigel Brooks Journal: Mol Cancer Ther Date: 2013-07-16 Impact factor: 6.261